US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

OPUS GENETICS INC

4.08

-0.0800-1.92%

Volume:494.80K

Turnover:1.99M

Market Cap:281.37M

PE:-2.19

High:4.18

Open:4.08

Low:3.83

Close:4.16

52wk High:4.18

52wk Low:0.6500

Shares:68.96M

Float Shares:63.12M

Volume Ratio:1.25

T/O Rate:0.78%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.8600

EPS(LYR):-2.1535

ROE:-338.75%

ROA:-60.73%

PB:47.16

PE(LYR):-1.89

Loading ...

Overview Company News Filings

Opus Genetics Grants Stock Options to New Employees Under Inducement Plan

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW, Kohl's

Opus Genetics Initiated at Overweight by Piper Sandler

BUZZ-Opus Genetics gets 'overweight' rating as Piper Sandler initiates coverage

Analysts’ Top Healthcare Picks: Amgen (AMGN), Opus Genetics (IRD)

Opus Genetics Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $7

THOMSON REUTERS

Opus Genetics CEO to Speak at Piper Sandler Healthcare Conference

Opus Genetics Is Maintained at Buy by Chardan Capital

Opus Genetics Inc - Initial Data From Trial Expected in Q1 2026

THOMSON REUTERS

Opus Genetics Announces Dosing of First Participant in Opgx-Best1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

THOMSON REUTERS

Opus Genetics reports third quarter results and raises $23 million in equity offering

Press Release: Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

Opus Genetics Inc expected to post a loss of 13 cents a share - Earnings Preview

Opus Genetics Is Maintained at Buy by Chardan Capital

Analysts’ Top Healthcare Picks: Elanco Animal Health (ELAN), Opus Genetics (IRD)

Opus Genetics Inc - Selling 3.8 Mln Shares at $2.09 per Share

THOMSON REUTERS

Opus Genetics Inc - Proceeds to Advance Lca5 and Best-1 Gene Therapy Programs

THOMSON REUTERS

Opus Genetics Inc: Intends to Apply for FDA's New Rare Disease Evidence Principles (Rdep) Review Process

THOMSON REUTERS

Opus Genetics Grants Equity Awards to New Executive and Employee

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IRD/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","market":"US","secType":"STK","nameCN":"OPUS GENETICS INC","latestPrice":4.08,"timestamp":1772472130495,"preClose":4.16,"halted":0,"volume":494802,"delay":0,"changeRate":-0.019230769230769246,"floatShares":63122173,"shares":68964208,"eps":-1.86,"marketStatus":"Trading","change":-0.08,"latestTime":"03-02 12:22:22 EST","open":4.08,"high":4.18,"low":3.8306,"amount":1993278.0412314,"amplitude":0.08399,"askPrice":4.09,"askSize":132,"bidPrice":4.07,"bidSize":72,"shortable":3,"etf":0,"ttmEps":-1.86,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772485200000},"marketStatusCode":2,"adr":0,"listingDate":1100235600000,"exchange":"NASDAQ","adjPreClose":4.16,"preHourTrading":{"tag":"盘前","latestPrice":4.12,"preClose":4.16,"latestTime":"09:29 EST","volume":19418,"amount":75190.49610799999,"timestamp":1772461799417,"change":-0.04,"changeRate":-0.009615,"amplitude":0.105769},"postHourTrading":{"tag":"盘后","latestPrice":4.1483,"preClose":4.16,"latestTime":"19:57 EST","volume":12808,"amount":53157.8576,"timestamp":1772240273728,"change":-0.0117,"changeRate":-0.002812,"amplitude":0.007212},"volumeRatio":1.245068,"impliedVol":2.2678,"impliedVolPercentile":0.9761},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","floatShares":63122173,"roa":"-60.73%","roe":"-338.75%","lyrEps":-2.153504,"volumeRatio":1.245068,"shares":68964208,"dividePrice":0,"high":4.18,"amplitude":0.08399,"preClose":4.16,"low":3.8306,"week52Low":0.65,"pbRate":"47.16","psRate":"19.23","week52High":4.18,"institutionHeld":0,"latestPrice":4.08,"committee":-0.294118,"eps":-1.86,"divideRate":0,"volume":494802,"delay":0,"ttmEps":-1.86,"open":4.08,"prevYearClose":2.01,"prevWeekClose":4.16,"prevMonthClose":4.16,"prevQuarterClose":2.01,"fiveDayClose":3.45,"twentyDayClose":2.31,"sixtyDayClose":1.99},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"IRD","fiscalQuarterEnding":"2025/09","expectedEps":-0.14,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.12},{"market":"US","date":"2025-08-13","symbol":"IRD","fiscalQuarterEnding":"2025/06","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.12},{"market":"US","date":"2025-05-15","symbol":"IRD","fiscalQuarterEnding":"2025/03","expectedEps":-0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.32},{"market":"US","date":"2025-03-31","symbol":"IRD","fiscalQuarterEnding":"2024/12","expectedEps":-0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":-1.27},{"market":"US","date":"2024-11-12","symbol":"IRD","fiscalQuarterEnding":"2024/09","expectedEps":-0.3,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.29}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.8333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":12,"updateTime":1769490000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IRD","date":"2026-02-27","current":-2.236559,"percent":0.012048,"low":-3.933416,"twenty":-2.153773,"median":-1.330709,"eighty":-1.044184,"high":-0.560128,"avg":-1.579118,"sd":0.69548,"marketCap":247581506},"quantilePoints":[{"date":"2024-10-31","current":-2.785848,"twenty":-2.857166,"median":-2.64666,"eighty":-2.37374,"marketCap":39294383},{"date":"2024-11-08","current":-2.429259,"twenty":-2.692243,"median":-2.607554,"eighty":-2.476187,"marketCap":34264702},{"date":"2024-11-15","current":-1.225421,"twenty":-2.616468,"median":-2.568551,"eighty":-2.326813,"marketCap":33321637},{"date":"2024-11-22","current":-1.142487,"twenty":-2.607554,"median":-2.49612,"eighty":-1.192247,"marketCap":31066518},{"date":"2024-11-29","current":-1.288651,"twenty":-2.607554,"median":-2.173143,"eighty":-1.193702,"marketCap":35040987},{"date":"2024-12-06","current":-1.323479,"twenty":-2.603096,"median":-1.364112,"eighty":-1.225421,"marketCap":35988040},{"date":"2024-12-13","current":-1.288651,"twenty":-2.574123,"median":-1.335088,"eighty":-1.234669,"marketCap":35040987},{"date":"2024-12-20","current":-1.14597,"twenty":-2.527405,"median":-1.303163,"eighty":-1.16559,"marketCap":31161223},{"date":"2024-12-27","current":-1.253822,"twenty":-2.505202,"median":-1.288651,"eighty":-1.163268,"marketCap":34093933},{"date":"2025-01-03","current":-1.462793,"twenty":-2.49612,"median":-1.294455,"eighty":-1.172556,"marketCap":39776255},{"date":"2025-01-10","current":-1.683372,"twenty":-2.442631,"median":-1.320577,"eighty":-1.181843,"marketCap":45774262},{"date":"2025-01-17","current":-1.346698,"twenty":-2.224366,"median":-1.346698,"eighty":-1.20274,"marketCap":36619410},{"date":"2025-01-24","current":-1.335088,"twenty":-1.87928,"median":-1.335088,"eighty":-1.207384,"marketCap":36303725},{"date":"2025-01-31","current":-1.288651,"twenty":-1.676407,"median":-1.329284,"eighty":-1.218206,"marketCap":35040987},{"date":"2025-02-07","current":-1.416355,"twenty":-1.657832,"median":-1.323479,"eighty":-1.225421,"marketCap":38513517},{"date":"2025-02-14","current":-1.335088,"twenty":-1.648544,"median":-1.323479,"eighty":-1.239294,"marketCap":36303725},{"date":"2025-02-21","current":-1.288651,"twenty":-1.616038,"median":-1.323479,"eighty":-1.250654,"marketCap":35040987},{"date":"2025-02-28","current":-1.207384,"twenty":-1.525484,"median":-1.317674,"eighty":-1.232138,"marketCap":32831195},{"date":"2025-03-07","current":-1.160946,"twenty":-1.444218,"median":-1.31187,"eighty":-1.207384,"marketCap":31568457},{"date":"2025-03-14","current":-1.07968,"twenty":-1.411711,"median":-1.30026,"eighty":-1.1772,"marketCap":29358665},{"date":"2025-03-21","current":-1.335088,"twenty":-1.404745,"median":-1.30026,"eighty":-1.16559,"marketCap":36303725},{"date":"2025-03-28","current":-1.637559,"twenty":-1.525484,"median":-1.31187,"eighty":-1.1772,"marketCap":44528506},{"date":"2025-04-04","current":-0.76585,"twenty":-1.525484,"median":-1.306065,"eighty":-1.160946,"marketCap":44060874},{"date":"2025-04-11","current":-0.564318,"twenty":-1.462793,"median":-1.288651,"eighty":-1.14388,"marketCap":32466352},{"date":"2025-04-17","current":-0.581158,"twenty":-1.453505,"median":-1.288651,"eighty":-1.129154,"marketCap":33435158},{"date":"2025-04-25","current":-0.632466,"twenty":-1.414033,"median":-1.288651,"eighty":-1.081468,"marketCap":36387058},{"date":"2025-05-02","current":-0.741567,"twenty":-1.404745,"median":-1.288651,"eighty":-1.054291,"marketCap":42663825},{"date":"2025-05-09","current":-0.787263,"twenty":-1.404745,"median":-1.277041,"eighty":-0.791089,"marketCap":45292790},{"date":"2025-05-16","current":-0.737114,"twenty":-1.402423,"median":-1.253822,"eighty":-0.755291,"marketCap":43209631},{"date":"2025-05-23","current":-0.783669,"twenty":-1.393136,"median":-1.253822,"eighty":-0.759832,"marketCap":45938661},{"date":"2025-05-30","current":-0.771642,"twenty":-1.393136,"median":-1.251182,"eighty":-0.76585,"marketCap":45233661},{"date":"2025-06-06","current":-1.017762,"twenty":-1.393136,"median":-1.225421,"eighty":-0.767335,"marketCap":59661197},{"date":"2025-06-13","current":-1.009213,"twenty":-1.381526,"median":-1.207384,"eighty":-0.771254,"marketCap":59160042},{"date":"2025-06-20","current":-0.947842,"twenty":-1.372239,"median":-1.207384,"eighty":-0.771564,"marketCap":55562472},{"date":"2025-06-27","current":-1.038117,"twenty":-1.360629,"median":-1.184165,"eighty":-0.771642,"marketCap":60854420},{"date":"2025-07-03","current":-1.017762,"twenty":-1.358307,"median":-1.160946,"eighty":-0.77653,"marketCap":59661197},{"date":"2025-07-11","current":-1.139893,"twenty":-1.351342,"median":-1.160017,"eighty":-0.782117,"marketCap":66820540},{"date":"2025-07-18","current":-1.185692,"twenty":-1.346698,"median":-1.152239,"eighty":-0.783669,"marketCap":69505294},{"date":"2025-07-25","current":-1.231492,"twenty":-1.339732,"median":-1.160017,"eighty":-0.783669,"marketCap":72190048},{"date":"2025-08-01","current":-1.129716,"twenty":-1.335088,"median":-1.160248,"eighty":-0.785825,"marketCap":66223928},{"date":"2025-08-08","current":-1.10936,"twenty":-1.335088,"median":-1.151155,"eighty":-0.789762,"marketCap":65030704},{"date":"2025-08-15","current":-1.213067,"twenty":-1.335088,"median":-1.150071,"eighty":-0.791428,"marketCap":70691504},{"date":"2025-08-22","current":-1.177087,"twenty":-1.335088,"median":-1.151155,"eighty":-0.791428,"marketCap":68594722},{"date":"2025-08-29","current":-1.287434,"twenty":-1.335088,"median":-1.160248,"eighty":-0.791428,"marketCap":75025207},{"date":"2025-09-05","current":-1.384803,"twenty":-1.335088,"median":-1.160946,"eighty":-0.797415,"marketCap":80699383},{"date":"2025-09-12","current":-1.525447,"twenty":-1.342054,"median":-1.174821,"eighty":-0.822134,"marketCap":88895414},{"date":"2025-09-19","current":-1.611997,"twenty":-1.365273,"median":-1.182227,"eighty":-0.876364,"marketCap":93939125},{"date":"2025-09-26","current":-1.860829,"twenty":-1.384803,"median":-1.184928,"eighty":-0.929339,"marketCap":108439795},{"date":"2025-10-03","current":-1.947379,"twenty":-1.400101,"median":-1.195775,"eighty":-0.939944,"marketCap":113483507},{"date":"2025-10-10","current":-2.152936,"twenty":-1.42988,"median":-1.207384,"eighty":-0.94314,"marketCap":125462322},{"date":"2025-10-17","current":-2.174573,"twenty":-1.477844,"median":-1.207384,"eighty":-0.951343,"marketCap":126723249},{"date":"2025-10-24","current":-2.163754,"twenty":-1.521119,"median":-1.217191,"eighty":-0.957164,"marketCap":126092786},{"date":"2025-10-31","current":-2.131298,"twenty":-1.627334,"median":-1.225421,"eighty":-0.958345,"marketCap":124201394},{"date":"2025-11-07","current":-2.196211,"twenty":-1.661499,"median":-1.23256,"eighty":-0.960734,"marketCap":127984177},{"date":"2025-11-14","current":-2.001473,"twenty":-1.74585,"median":-1.242213,"eighty":-0.964942,"marketCap":116635827},{"date":"2025-11-21","current":-1.951541,"twenty":-1.828372,"median":-1.253822,"eighty":-0.975077,"marketCap":133100921},{"date":"2025-11-28","current":-2.153773,"twenty":-1.878321,"median":-1.253822,"eighty":-0.98727,"marketCap":146893763},{"date":"2025-12-05","current":-2.254889,"twenty":-1.925381,"median":-1.265432,"eighty":-0.988735,"marketCap":153790183},{"date":"2025-12-12","current":-2.467233,"twenty":-1.950709,"median":-1.277041,"eighty":-0.996674,"marketCap":168272667},{"date":"2025-12-19","current":-2.002099,"twenty":-2.002099,"median":-1.288651,"eighty":-1.007767,"marketCap":136549131},{"date":"2025-12-26","current":-2.062768,"twenty":-2.022322,"median":-1.288651,"eighty":-1.0085,"marketCap":140686984},{"date":"2026-01-02","current":-2.032433,"twenty":-2.02248,"median":-1.288651,"eighty":-1.00907,"marketCap":138618058},{"date":"2026-01-09","current":-2.022322,"twenty":-2.035652,"median":-1.288651,"eighty":-1.009619,"marketCap":137928416},{"date":"2026-01-16","current":-2.103215,"twenty":-2.062768,"median":-1.30026,"eighty":-1.016154,"marketCap":143445552},{"date":"2026-01-23","current":-2.527902,"twenty":-2.079519,"median":-1.303662,"eighty":-1.017762,"marketCap":172410520},{"date":"2026-01-30","current":-2.527902,"twenty":-2.105793,"median":-1.31187,"eighty":-1.017762,"marketCap":172410520},{"date":"2026-02-06","current":-2.608795,"twenty":-2.126582,"median":-1.317674,"eighty":-1.019861,"marketCap":177927656},{"date":"2026-02-13","current":-3.427836,"twenty":-2.136977,"median":-1.323479,"eighty":-1.031375,"marketCap":233788665},{"date":"2026-02-20","current":-3.609844,"twenty":-2.149226,"median":-1.323479,"eighty":-1.038117,"marketCap":246202222},{"date":"2026-02-27","current":-3.630068,"twenty":-2.153773,"median":-1.330709,"eighty":-1.044184,"marketCap":247581506}],"updateTime":1772454824136},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IRD\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588578066","title":"Opus Genetics Grants Stock Options to New Employees Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2588578066","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588578066?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:01","pubTimestamp":1764709271,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc. has granted equity awards to two new non-executive employees under its 2021 Inducement Plan. The awards consist of options to purchase a total of 124,000 shares of the company's common stock. The options have an exercise price set at the fair market value on the grant date and will vest over four years, with 25% vesting after one year and the remaining 75% vesting in quarterly installments. Vesting may accelerate or be forfeited based on certain events specified in the award agreements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 02, 2025, and is solely responsible for the information contained therein","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL6VGFJx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4112","IRD","LU2210149790.SGD","IE00BGHQF748.EUR","BK4588","BK4139","IE00B3QW5Z07.USD","BK4007","BK4585","IE00BKPKM429.USD","LU0314104364.USD","IE00B64PRP62.GBP","LU2210150020.SGD","NDAQ"],"gpt_icon":0},{"id":"2588066594","title":"Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588066594","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588066594?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:01","pubTimestamp":1764709260,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA2MT1XC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","IRD"],"gpt_icon":0},{"id":"2586724874","title":"BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW,  Kohl's","url":"https://stock-news.laohu8.com/highlight/detail?id=2586724874","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586724874?lang=en_us&edition=fundamental","pubTime":"2025-11-25 23:45","pubTimestamp":1764085504,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW, Kohl'sEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: htt","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL6N3X10WK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DD","FLNC","CDE","BBY","FLY","LU0323591593.USD","HL","LU2290526834.HKD","LU1066051498.USD","ZM","APD","BK4541","ZETA","KEYS","LU1116320737.USD","FIBK","FCX","BK4548","SCCO","UPWK","SPOT","ANF","SYM","ESPR","PTCT","LU1815336760.USD","SG9999000418.SGD","ATAT","CDW","AMAT","ALUR","LU0784383803.USD","SRPT","IRD","ABCB","TITN","LIXT","KSS","ADI","VST","IE00BN0W2T93.GBP"],"gpt_icon":1},{"id":"2586479046","title":"Opus Genetics Initiated at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2586479046","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586479046?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:31","pubTimestamp":1764081060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 25, 2025 09:31 ET (14:31 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IRD","BK4007"],"gpt_icon":0},{"id":"2586203134","title":"BUZZ-Opus Genetics gets 'overweight' rating as Piper Sandler initiates coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=2586203134","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586203134?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:03","pubTimestamp":1764072213,"startTime":"0","endTime":"0","summary":"BUZZ-Opus Genetics gets 'overweight' rating as Piper Sandler initiates coverage** Piper Sandler initiates coverage on Opus Genetics IRD.O with an \"overweight\" rating; sets PT at $7, reflecting about 250% upside on the stock's last close** Shares of clinical-stage biopharmaceutical company rise 4.5% to $2.09 premarket  ** Brokerage is bullish about IRD following strong early clinical data for its lead program OPGx-LCA5 in an ultra-rare eye disease ** Piper Sandler notes how the company is targeting ultra-rare diseases first like LCA5 and BEST1 where competition is minimal and regulatory pathways are often faster** All eight brokerages rate the stock \"buy\" or higher; their median PT is $8 - data compiled by LSEG** As of last close, IRD stock is up ~68.1%  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL6N3X10OR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","IRD"],"gpt_icon":0},{"id":"2586421831","title":"Analysts’ Top Healthcare Picks: Amgen (AMGN), Opus Genetics (IRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2586421831","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586421831?lang=en_us&edition=fundamental","pubTime":"2025-11-25 18:10","pubTimestamp":1764065412,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen (AMGN – Research Report) and Opus Genetics (IR...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-amgen-amgn-opus-genetics-ird-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-amgen-amgn-opus-genetics-ird-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","LU1061106388.HKD","BK4599","LU0029874061.USD","LU0058720904.USD","BK4585","BK4588","HCSG","IRD","XLV","LU0320765992.SGD","IE0002141913.USD","LU2089984988.USD","XBI","LU0289739699.SGD","IE00B4R5TH58.HKD","LABU","BK4581","LU2112291526.USD","LU1571399168.USD","LU1057294990.SGD","LU0889565916.HKD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4137","BK4566","LU0122379950.USD","BK4534","LU1983299246.USD","IE0009355771.USD","LU2468319806.SGD","IE00BJJMRZ35.SGD","SG9999001440.SGD","LU0109394709.USD","BK4007","LU1023059063.AUD","BK4139","LU2242652126.USD","IE00BFTCPJ56.SGD","LU0868494617.USD","BK4533","LU2242646821.SGD","AMGN"],"gpt_icon":0},{"id":"2586842896","title":"Opus Genetics Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2586842896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586842896?lang=en_us&edition=fundamental","pubTime":"2025-11-25 16:34","pubTimestamp":1764059685,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nFWN3X10BO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","IRD"],"gpt_icon":0},{"id":"2584312931","title":"Opus Genetics CEO to Speak at Piper Sandler Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2584312931","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584312931?lang=en_us&edition=fundamental","pubTime":"2025-11-20 21:00","pubTimestamp":1763643635,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc., a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, will participate in the Piper Sandler 37th Annual Healthcare Conference. CEO George Magrath will join a fireside chat on December 2, 2025, at 10:00 a.m. ET in New York, NY.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 20, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL1WmzV2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK4585","LU2095319765.USD","LU2210150020.SGD","LU0314104364.USD","BK4588","PIPR","LU2210149790.SGD","IE00BKPKM429.USD","BK4127","IE00B64PRP62.GBP","BK4007","IE00B3QW5Z07.USD","BK4112","IE00BGHQF748.EUR","BK4139","IRD"],"gpt_icon":0},{"id":"2583930425","title":"Opus Genetics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2583930425","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583930425?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:52","pubTimestamp":1763041920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 08:52 ET (13:52 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","IRD"],"gpt_icon":0},{"id":"2583564756","title":"Opus Genetics Inc - Initial Data From Trial Expected in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2583564756","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583564756?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:00","pubTimestamp":1763035202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA5WBXNM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4139","BK4007"],"gpt_icon":0},{"id":"2583172564","title":"Opus Genetics Announces Dosing of First Participant in Opgx-Best1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2583172564","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583172564?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:00","pubTimestamp":1763035202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA5WBXNM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","IRD"],"gpt_icon":0},{"id":"2582373073","title":"Opus Genetics reports third quarter results and raises $23 million in equity offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373073","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373073?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:01","pubTimestamp":1762948888,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc. reported cash and cash equivalents of $30.8 million as of September 30, 2025. After the quarter ended, the company raised approximately $23.0 million in gross proceeds through a registered direct equity offering, bringing its cash position to over $50 million. The company expects these funds to support operations into the second half of 2027. During the period, Opus Genetics advanced its pipeline, highlighted by positive clinical data in its OPGx-LCA5 Phase 1/2 trial and ongoing recruitment in the OPGx-BEST1 Phase 1/2 trial. The company also plans to submit a supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for presbyopia by year-end 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLHhMhR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","LU2095319765.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","NDAQ","IE00B64PRP62.GBP","BK4112","IE00BGHQF748.EUR","LU2210149790.SGD","IRD","LU0314104364.USD","BK4007","BK4585"],"gpt_icon":0},{"id":"2582373217","title":"Press Release: Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373217","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373217?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948800,"startTime":"0","endTime":"0","summary":"- Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for restoring cone-mediated vision -. - Successful FDA RMAT meeting provides the potential for an accelerated regulatory pathway to approval for OPGx-LCA5 -. - OPGx-BEST1 gene therapy program underway with recruitment ongoing in Phase 1/2 trial for the treatment of BEST1 disease -. - Supplemental New Drug Application submission planned by year-end 2025 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -. - Strengthened capital position from recent equity offering and non-dilutive funding from patient advocacy groups -. \"We have taken critical steps in advancing our pipeline, including the positive data and successful outcome of our recent FDA meeting regarding our LCA5 program and the opening of recruitment in our BEST1 Phase 1/2 clinical trial,\" said George Magrath, M.D., Chief Executive Officer, Opus Genetics. \"We look forward to continuing this ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA","IRD","BK4139","BK4007","ARB"],"gpt_icon":0},{"id":"2581793884","title":"Opus Genetics Inc  expected to post a loss of 13 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581793884","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581793884?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:32","pubTimestamp":1762529525,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc  expected to post a loss of13cents a share - Earnings Preview Opus Genetics Inc IRD.OQ IRD.O is expected to  show a fall in quarterly revenue when it reports  results on November 10 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ25U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","IRD"],"gpt_icon":0},{"id":"2581884897","title":"Opus Genetics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2581884897","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581884897?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:05","pubTimestamp":1762527900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 10:05 ET (15:05 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4139","BK4007"],"gpt_icon":0},{"id":"2581018153","title":"Analysts’ Top Healthcare Picks: Elanco Animal Health (ELAN), Opus Genetics (IRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581018153","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581018153?lang=en_us&edition=fundamental","pubTime":"2025-11-07 00:20","pubTimestamp":1762446036,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Elanco Animal Health (ELAN – Research Report), Opus ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-elanco-animal-health-elan-opus-genetics-ird-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-elanco-animal-health-elan-opus-genetics-ird-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRD","LU0128526141.USD","XLV","BK4137","BK4139","LU1941712348.USD","ELAN","HCSG","LU0029874061.USD","BK4585","BK4007","BK4581","LABU","XBI","BK4561","LU1941712264.USD","BK4588"],"gpt_icon":0},{"id":"2581393062","title":"Opus Genetics Inc - Selling 3.8 Mln Shares at $2.09 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2581393062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581393062?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA7HRKW3:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD","BK4139"],"gpt_icon":0},{"id":"2581062357","title":"Opus Genetics Inc - Proceeds to Advance Lca5 and Best-1 Gene Therapy Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2581062357","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581062357?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA7HRKW3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","IRD"],"gpt_icon":0},{"id":"2581620380","title":"Opus Genetics Inc: Intends to Apply for FDA's New Rare Disease Evidence Principles (Rdep) Review Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2581620380","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581620380?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA3ZZ4R2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","IRD"],"gpt_icon":0},{"id":"2581769792","title":"Opus Genetics Grants Equity Awards to New Executive and Employee","url":"https://stock-news.laohu8.com/highlight/detail?id=2581769792","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581769792?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:02","pubTimestamp":1762290130,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc. has announced new equity awards for two recently hired employees, including James Farrell, the newly appointed Executive Director of Business Development. Farrell received an option to purchase 175,000 shares of company common stock, while another non-executive employee received an option for 189,448 shares. The options have an exercise price set at the fair market value on the grant date and will vest over four years, with 25% vesting after one year and the remaining 75% vesting in quarterly installments thereafter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 04, 2025, and is solely responsible for th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL6wrJkQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210149790.SGD","BK4585","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","BK4139","IRD","IE00B3QW5Z07.USD","LU2210150020.SGD","LU0314104364.USD","BK4007","NDAQ","LU2095319765.USD","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":74,"code":"91000000","status":"200"}]}}